RESEARCH ARTICLE

Long term miscarriage-related hypertension and diabetes mellitus. Evidence from a United Kingdom population-based cohort study

Kelvin Okoth¹, Anuradhaa Subramanian¹, Joht Singh Chandan¹, Nicola J. Adderley¹, G. Neil Thomas¹, Krishnarajah Nirantharakumar¹*, Christina Antza²

¹ Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, ² Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom

* These authors contributed equally to this work.
∴ k.nirantharan@bham.ac.uk

Abstract

Background

Miscarriages affect up to a fifth of all pregnancies and are associated with substantial psychological morbidity. However, their relationship with cardiometabolic risk factors is not well known. Therefore, in this study we aimed to estimate the burden of cardiovascular risk factors including diabetes mellitus (type 1 or 2) and hypertension in women with miscarriage compared to women without a record of miscarriage.

Methods

A population-based retrospective cohort study was conducted using IVQIA Medical Research Data UK (IMRD-UK) between January 1995 and May 2016, an anonymised electronic health records database that is representative of the UK population. A total of 86,509, 16–50-year-old women with a record of miscarriage (exposed group) were matched by age, smoking status, and body mass index to 329,865 women without a record of miscarriage (unexposed group). Patients with pre-existing hypertension and diabetes were excluded. Adjusted incidence rate ratios (aIRR) and 95% confidence intervals (95% CI) for diabetes and hypertension were estimated using multivariable Poisson regression models offsetting for person-years follow-up.

Results

The mean age at cohort entry was 31 years and median follow up was 4.6 (IQR 1.7–9.4) years. During the study period, a total of 792 (IR 1.44 per 1000 years) and 2525 (IR 1.26 per 1000 years) patients developed diabetes in the exposed and unexposed groups, respectively. For hypertension, 1995 (IR 3.73 per 1000 years) and 1605 (IR 3.39 per 1000 years) new diagnoses were recorded in the exposed and unexposed groups, respectively. Compared to unexposed individuals, women with a record miscarriage were more likely to develop diabetes (aIRR = 1.25, 95% CI: 1.15–1.36; p<0.001) and hypertension (aIRR = 1.07, 95% CI: 1.02–1.12; p = 0.005).
Conclusions

Women diagnosed with miscarriage were at increased risk of developing diabetes mellitus and hypertension. Women with history of miscarriage may benefit from periodic monitoring of their cardiometabolic health.

Introduction

Non-communicable diseases are the leading cause of mortality worldwide accounting for almost 70% of global deaths [1]. Diabetes mellitus and hypertension are some of the most important non-communicable diseases, with diabetes responsible for 4% of non-communicable deaths while 19% of the global deaths are attributable to hypertension [1,2]. Recent statistics show that 3.5 million people live with diabetes in the United Kingdom (UK), while up to 30% of the adult population have hypertension [3]. As these numbers continue to increase, identifying further risk factors for diabetes and hypertension is of great importance for early prevention and treatment.

Conventional and well-studied risk factors common to the development of cardiovascular disease and risk factors such as hypertension and diabetes include obesity, physical inactivity, family history, ethnicity, poor dietary habits, and smoking [4–7]. In addition, emerging research has shown that exposure to some obstetric complications, among them miscarriage, may be risk factors for the development of future maternal cardio-metabolic outcomes [8]. Miscarriage is defined as the spontaneous loss of pregnancy prior to foetal viability, from conception up to 24 weeks gestation, and is the most common pregnancy complication [9]. Estimates show that up to a third of all biochemical pregnancies and up to a fifth of all clinical pregnancies end up as miscarriage [9,10].

Pre-eclampsia and other obstetric complications have been included in the American Heart Association guidelines as cardiovascular risk factors for women, but miscarriage was omitted despite the fact that some of these complications share common pathological origins with miscarriage [11]. Furthermore, research through large population studies and meta-analyses has confirmed the strong association of miscarriage with cardiovascular outcomes, providing another reason for scientists to consider miscarriage in the assessment of future cardiovascular risk [12–14]. However, the link between miscarriage and the subsequent development of cardiovascular disease are not well argued or documented. There is limited evidence describing common risk factors such as family history of cardiovascular diseases, obesity, smoking and endothelial dysfunction [15–17] while other cardiovascular risk factors, such as diabetes and especially hypertension remain under explored.

Hence, the aim of this study was to conduct a population-based retrospective matched cohort to investigate the rates of diabetes and hypertension among women in the UK with incident miscarriage compared to women with an otherwise normal pregnancy who have not experienced miscarriage.

Methods

Study design

We conducted a population-based, retrospective open cohort study, to estimate the risk of developing diabetes (type 1 or type 2) and hypertension in women who experienced a
miscarriage (exposed) compared to those who had not (unexposed), between 1st January 1995 and 15th May 2016.

Data source
The study used data from general practices in the UK contributing to the IMRD-UK database. The database contains more than 3 million active patients from over 700 participating general practices spread across the UK. The individuals contributing to the database are representative of the UK population [18]. The dataset consists of recorded medical diagnoses, medical prescriptions, socio-demographic details, and information from hospital admissions. Participating practices collect patient data using an electronic health record system called Vision software. Medical diagnoses and other related patient data are recorded using a hierarchical coding system called Read codes [19]. A wide range of medical conditions using IMRD-UK database have been validated, including cardiovascular diseases and diabetic conditions [20,21]. The process for selecting Read codes for the exposure and outcomes are documented in the text in S1 Table. Data extraction and cohort selection were facilitated using the Data Extraction for Epidemiological Research (DExtER) tool [22].

Practice eligibility criteria. Practices were eligible for inclusion from the later of the date when the practice met the acceptable mortality reporting standard and one year after the practice implemented use of the Vision software system to allow for sufficient time for the recording of important patient data [23].

Study population
Adult women aged 16–50 years at study entry date were eligible for inclusion in the study estimating incidence rate of diabetes and hypertension. Participant entry into the study was at the latest of their 16th birthday, one year after registration with an eligible practice, or study start date.

Exposure
Women with a Read code record of miscarriage diagnosis (exposure) were matched with up to four women without a record of miscarriage (unexposed) randomly selected from the pool of patients with a record of a previous pregnancy carried to delivery. The exposed and unexposed participants were matched by age (within 1 year), body mass index (BMI: +/-2 kg/m²) and smoking status.

Follow up period
The date of diagnosis of miscarriage served as the index date for newly diagnosed patients (incidence cases). To mitigate immortal time bias, matched unexposed patients were assigned the same index date as their corresponding exposed patients. The follow up period was defined as the time between the patient’s index date and exit date. The exit date was defined as the earliest of (i) a diagnosis of type 1 or 2 diabetes or hypertension, (ii) death of patient, (iii) study end date, (iv) patient left the practice, (v) last data collection from the practice.

Outcomes
The outcome was the incident diagnosis of either diabetes mellitus (type 1 or 2) or hypertension. The outcomes were identified using the relevant Read codes. Both outcomes are part of the quality outcomes framework (QOF) and are well recorded in primary care settings [18].
Ethical approval

IQVIA Medical Research Data (IMRD) incorporates data from The Health Improvement Network (THIN) a Cegedim database [24]. Reference made to THIN is intended to be descriptive of the data asset licensed by IQVIA.

Anonymised data were used throughout the study provided by the data provider to the University of Birmingham. Studies using IMRD-UK database have had initial ethical approval from the NHS South-East Multicentre Research Ethics Committee, subject to prior independent scientific review. The Scientific Review Committee (IQVIA) approved the study protocol (SRC Reference Number: 17THIN075).

Study covariates

The following potential confounders were included in the study: age, Townsend quintiles of deprivation, smoking status, BMI, lipid medication (current users), connective tissue disorders, and reproductive comorbidities (pre-eclampsia, gestational diabetes mellitus) [25].

For each of the study covariates the most recently documented record prior to study entry was used. Self-reported smoking status was categorised as never smoker, ex-smoker, current smoker or missing. BMI measured in kg/m$^2$ was categorised as underweight or normal (<25 kg/m$^2$), overweight (25–30 kg/m$^2$), obese (>30 kg/m$^2$), and missing for those with missing or implausible values. A record for prescription of lipid-lowering medication was used as a proxy for high cholesterol levels. Patients prescribed lipid medication within the last sixty days prior to cohort entry were defined as current users. Connective tissue disorders (CTD) are a group of autoimmune diseases which include systemic lupus erythematosus, polymyalgia rheumatica, polymyositis, and rheumatoid arthritis.

Statistical analysis

Continuous variables were presented as mean ± standard deviation (SD) or median and interquartile range (IQR) depending on their distribution, and proportions were used for categorical variables.

Incidence rates (IR) were calculated for each outcome separately. These were estimated as the number of incident cases of the outcome divided by the total number of person-years follow up. The person-years follow up was from the entry date to the exit date. Incidence rates were expressed as per 1000 person-years at risk.

Poisson regression models offsetting for person-years follow-up, were used to estimate incidence rate ratios (IRR) and 95% confidence intervals by making comparisons between those with a record of miscarriage (exposed) to those without a record of miscarriage (unexposed). Crude and adjusted IRRs were calculated. Patients with a record of the outcome at baseline were excluded from the corresponding analysis. For example, for the analysis examining the association between miscarriage and diabetes, patients with diabetes at baseline were excluded from the analysis. Statistical significance was set at p<0.05. Regression models were adjusted for age, Townsend quintile of deprivation, smoking status, BMI, polycystic ovary syndrome (PCOS), connective tissue disorders, pre-eclampsia, and gestational diabetes mellitus. Statistical analysis was performed using Stata version 14.2 (Stata Corps, College Station, Texas, USA).

Results

Population characteristics

Following application of inclusion/exclusion criteria, the final study population comprised 416,374 women aged between 16–50 years. Fig 1 presents the study participants flow chart.
86,509 women with a record of miscarriage were included in the exposed population, and 329,865 women without a record of miscarriage were included in the unexposed population. The median duration of follow-up in the miscarriage cohort was 4.8 (IQR 1.9–9.4) years, while in the unexposed cohort it was 4.4 (IQR 1.6–9.1) years.

Table 1 summarises the baseline characteristics by exposure status. Overall, the participant characteristics between the two groups were broadly similar. However, compared to women without a record of miscarriage, women with a record of miscarriage were more likely to be ex-smokers (14.2% versus 13.6%) and be diagnosed with PCOS (3.4% versus 2.9%), while they were less likely to be diagnosed with gestational diabetes (0.8% versus 1.6%).

Diabetes mellitus

During follow up, there were a total of 792 incident diagnoses of type 1 or 2 diabetes in the miscarriage group, while 2,525 incident diagnoses of diabetes were reported in the unexposed group. The incidence rate per 1000 person-years at risk in the miscarriage cohort and the
unexposed cohort was 1.44 and 1.26, respectively. Women exposed to miscarriage had a 15% higher incidence of diabetes compared to women unexposed to miscarriage (crude IRR = 1.15, 95% CI: 1.06–1.24, \( p = 0.001 \)). After adjustment for age, BMI, Townsend deprivation index, smoking, lipid profile, connective tissue disorders, gestational diabetes mellitus, PCOS and pre-eclampsia, a record of miscarriage was associated with a 25% (IRR = 1.25, 95% CI: 1.15–1.36, \( p < 0.001 \)) higher incidence of diabetes compared to women in the unexposed group. The results are summarised in Table 2.

### Hypertension

During the follow up period, there were 1,995 incident diagnoses of hypertension among women with a record of miscarriage and 6,637 incident diagnoses among women without a record of miscarriage. The incidence rate per 1000 person-years at risk was 3.73 and 3.39 among women with and without a record of miscarriage, respectively. Compared to

---

**Table 1. Baseline characteristics of the study population.**

|                          | Exposed to miscarriage n = 86,509 | Unexposed to miscarriage n = 329,865 |
|--------------------------|-----------------------------------|---------------------------------------|
| Maternal Age, mean (SD)  | 30.9 (6.8)                        | 30.4 (6.5)                            |
| Body Mass Index, n (%)   |                                   |                                       |
| <25kg/m\(^2\)            | 41,494 (48)                       | 161,716 (49)                         |
| 25–30 kg/m\(^2\)        | 16,826 (19.5)                     | 68,045 (20.7)                        |
| >30 kg/m\(^2\)          | 11,398 (13.2)                     | 44,316 (13.4)                        |
| Missing                  | 16,791 (19.4)                     | 55,788 (16.9)                        |
| Smoking status, n (%)    |                                   |                                       |
| Non-smokers              | 47,146 (54.5)                     | 179,301 (54.4)                       |
| Ex-smokers               | 12,305 (14.2)                     | 44,757 (13.6)                        |
| Smokers (current)        | 20,948 (24.2)                     | 81,461 (24.7)                        |
| Missing                  | 6,110 (7.1)                       | 24,346 (7.4)                         |
| Use of lipid lowering medication, n (%) |                                   |                                       |
| On medication            | 370 (0.4)                         | 1174 (0.4)                           |
| Townsend deprivation Index, n (%) |                                   |                                       |
| 1 (Least deprived)       | 17,862 (20.7)                     | 68,708 (20.8)                        |
| 2                        | 15,997 (18.5)                     | 61,036 (18.5)                        |
| 3                        | 17,805 (20.6)                     | 67,313 (20.4)                        |
| 4                        | 16,464 (19.0)                     | 63,305 (19.2)                        |
| 5 (Most deprived)        | 12,638 (14.6)                     | 46,625 (14.1)                        |
| Missing                  | 5,743 (6.6)                       | 22,878 (6.9)                         |
| Co-morbidities at baseline, n (%) |                                   |                                       |
| Hypertension             | 1,150 (1.3)                       | 4,103 (1.2)                          |
| Diabetes                 | 734 (0.9)                         | 2,181 (0.7)                          |
| Ischaemic heart disease  | 31 (0.0)                          | 180 (0.1)                            |
| Atrial fibrillation      | 21 (0.0)                          | 100 (0.0)                            |
| Heart failure            | 13 (0.0)                          | 64 (0.0)                             |
| Stroke/ TIA              | 108 (0.1)                         | 425 (0.1)                            |
| Gestational diabetes     | 651 (0.8)                         | 5170 (1.6)                           |
| Pre-eclampsia            | 400 (0.5)                         | 2,539 (0.8)                          |
| Connective tissue disorders | 403 (0.5)                        | 1,365 (0.4)                          |
| Polycystic ovary syndrome | 2,918 (3.4)                       | 9,581 (2.9)                          |

SD = standard deviation; TIA = transient ischaemic attack.

[https://doi.org/10.1371/journal.pone.0261769.t001](https://doi.org/10.1371/journal.pone.0261769.t001)
unexposed women, women with a record of miscarriage were more likely to develop hypertension (crude IRR = 1.10, 95% CI: 1.05–1.16, p < 0.001). This result remained statistically significant (IRR = 1.07, 95% CI: 1.02–1.12, p = 0.005) in the fully adjusted model. The results are summarised in Table 2.

Discussion

The aim of this cohort study was to estimate the burden of the cardiovascular risk factors, diabetes (type 1 or 2) and hypertension, subsequent to miscarriage among women in the UK aged 16–50 years. Our analysis revealed that women with a record of miscarriage developed diabetes and hypertension at significantly higher rates compared to women without a record of miscarriage. These associations remained significant after adjustment for confounders, with exposure to miscarriage being associated with 25% and 7% higher rates of diabetes and hypertension, respectively.

There is limited published evidence describing the long-term outcomes of miscarriage relating to diabetes and hypertension. A range of pregnancy characteristics have been recorded as determinants for higher blood pressure later in a woman’s life [26]. In contrast to our findings, a Finnish cross-sectional study found no association between miscarriage and the risk of developing hypertension (OR 0.8; 95% CI, 0.7–1.1) [27]. A Danish cohort study that investigated the association between pregnancy loss and subsequent risk of atherosclerotic disease among women aged 12 years and above, reported that women exposed to miscarriage had a higher risk of developing secondary, reno-vascular hypertension (adjusted IRR 1.20; 95% CI, 1.05–1.38) [28]. However, information on key confounders such as BMI and socioeconomic status were missing from the Danish study, and biased effect estimates can therefore not be ruled out. We found a significant association between miscarriage and hypertension after adjustments for BMI, socioeconomic status, PCOS, gestational diabetes, and connective tissue disorders, conditions which may predispose to both miscarriage and hypertension. This may explain the lower effect estimates for hypertension that were reported in our study. The findings from our study are consistent the results of a US prospective cohort study which reported that women with early miscarriage (<12 weeks) had a slightly higher risk of hypertension (adjusted HR 1.06; 95% CI: 1.02–1.10) and type 2 diabetes (adjusted HR 1.20; 95% CI: 1.07–1.34) [29].
A Scottish retrospective cohort study published in 2003, investigated the association between reproductive factors, BMI and risk of diabetes. The study reported 70% (adjusted OR 1.70; 95% CI 0.82–3.52) higher odds of developing diabetes among women with a record of miscarriage compared to women without a record of miscarriage after adjustment for age and BMI only [30]. More comparable to the findings of our study, a German cohort study found that women with miscarriage had a 30% (HR 1.30; 95% CI 1.01–1.68) higher risk of developing diabetes after adjustment for a number of confounders [31]. In addition to age, BMI, socioeconomic status, and hyperlipidaemia, our model was further adjusted for gestational diabetes, polycystic ovary syndrome, and connective tissue disorders, as these conditions predispose to spontaneous pregnancy loss and have been identified as risk factors for the development of diabetes [32–36]. A study in a Chinese population also found a statistically significant increase in risk of diabetes in women with miscarriage compared to women without, the effect estimate was smaller (HR 1.03; 95% CI, 1.00–1.05) compared to women without a record of miscarriage [37].

The mechanisms linking miscarriage to future maternal risk of cardiometabolic outcomes are unclear but may involve endothelial dysfunction, genetics, and metabolic syndrome. Adverse pregnancy outcomes (APOs) including pre-eclampsia, gestational diabetes, miscarriage, and pre-term birth are linked to future maternal risk of cardiometabolic complications [25,35,38]. The common underlying etiology of these APOs are placental anomalies triggered by endothelial dysfunction. It is postulated that endothelial dysfunction persists for several years beyond APOs leading to future risk of vascular complications [16]. There is an association between miscarriage and family history of cardiovascular complications suggesting that there are shared genetic anomalies. A study by Smith et al noted that women with history of two or more pregnancy losses prior to their first delivery had higher risk of family history of coronary heart disease [17]. Women with history of miscarriage may have an underlying susceptibility to metabolic syndrome, a condition that manifests with a combination of high blood glucose, hypertension, obesity and dyslipidemia [39].

This study provides evidence describing the incidence of diabetes and hypertension after miscarriage compared to women with normal pregnancies in a large, well-powered cohort study that adjusted for a wide range of well-defined risk factors. However, despite the strengths of the study, the results should be interpreted taking into account its limitations. The study explored diabetes as a broad endpoint, therefore specific association between miscarriage and either type 1 or type 2 diabetes was not evaluated. Misclassification of the exposure (miscarriage) or the outcome (diabetes or hypertension) may occur as some patients may be undiagnosed or asymptomatic. We do not expect there to be a systematic difference in the recording of the outcomes among women with and without miscarriage. However, the effect of including the exposure or the outcome in the wrong cohort is not clear and may not necessarily bias the effect estimate towards the null [40]. Furthermore, miscarriage maybe under recorded in primary care and therefore the number of incident cases may be underestimated. Although our study shows an association between history of miscarriage and future maternal risk of diabetes or hypertension, there is potential for unmeasured confounding for example from factors such as pregnancy weight gain or micronutrient deficiencies which are poorly recorded in UK primary care.

In terms of clinical practice, results from this study suggest that women with a history of miscarriage might be considered for referral for hypertension and diabetes screening and follow up. Current diabetes and hypertension guidelines do not mention this population as a high-risk population for monitoring, but our evidence in combination with the previous literature suggesting that this population is also at higher risk for cardiovascular outcomes indicate
that these risk factors should be considered by clinicians [41,42]. Future research should be focused on the mechanism behind miscarriage and cardiometabolic risk.

Conclusion

To conclude, higher rates of diabetes and hypertension were observed among women exposed to miscarriage compared to those unexposed to miscarriage. Given that diabetes and hypertension are leading causes of morbidity and mortality, women with history of miscarriage may benefit from periodic monitoring of their cardiometabolic health. Future studies are required to confirm findings from the present study, clarify the biological mechanism behind the observed associations, and investigate whether interventions that prevent miscarriage will be effective in reducing the excess burden of diabetes and hypertension among women with miscarriage.

Supporting information

S1 Table. Search strategy based to read codes.
(DOCX)

Acknowledgments

Prior publication of the study in abstract form: No Transparency declaration: The lead author (the manuscript’s guarantor) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Author Contributions

Conceptualization: Kelvin Okoth, Joht Singh Chandan, Krishnarajah Nirantharakumar.

Formal analysis: Kelvin Okoth, Anuradhaa Subramanian, Joht Singh Chandan, Christina Antza.

Investigation: Kelvin Okoth.

Methodology: Kelvin Okoth.

Software: Anuradhaa Subramanian, Joht Singh Chandan, Nicola J. Adderley, G. Neil Thomas.

Supervision: Joht Singh Chandan, Nicola J. Adderley, G. Neil Thomas, Krishnarajah Nirantharakumar, Christina Antza.

Writing – original draft: Kelvin Okoth, Christina Antza.

Writing – review & editing: Anuradhaa Subramanian, Joht Singh Chandan, Nicola J. Adderley, G. Neil Thomas, Krishnarajah Nirantharakumar, Christina Antza.

References

1. WHO.int. Noncommunicable diseases [Internet]. [cited 2021 May 26]. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.

2. Forouzanfar MH, Afshin A, Alexander LT, Biryukov S, Brauer M, Cercy K, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8; 388(10053):1659–724. https://doi.org/10.1016/S0140-6736(16)31679-8 PMID: 27733284
3. Scholes S. Health Survey for England 2018: Adult health. 2019.

4. Kotsis V, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, et al. Obesity and cardiovascular risk: A call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: Part A: Mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. Vol. 36, Journal of Hypertension. Lippincott Williams and Wilkins; 2018. p. 1427–40. https://doi.org/10.1097/HJH.0000000000001730 PMID: 29634663

5. Antza C, Staboulis S, Natsis M, Doundoulakis I, Kotsis V. Obesity-Induced Hypertension: New Insights. Curr Pharm Des. 2017 Dec 4; 23(31). https://doi.org/10.2174/1381612823666170608083343 PMID: 28595525

6. Leskinen T, Stenholt S, Pulakka A, Pentti J, Kivimäki M, Vahtera J. Comparison between recent and long-term physical activity levels as predictors of cardiometabolic risk: A cohort study. BMJ Open. 2020 Feb 16; 10(2):e033797. https://doi.org/10.1136/bmjopen-2019-033797 PMID: 32066606

7. Huang D, Huang Y, Adams N, Nguyen TT, Nguyen QC. Twitter-Characterized Sentiment Towards Racial/Ethnic Minorities and Cardiovascular Disease (CVD) Outcomes. J Racial Ethn Heal Disparities. 2020 Oct 1; 7(5):888–900. https://doi.org/10.1007/s40615-020-00712-y PMID: 32020547

8. Lao TT. The mother—The long-term implications on metabolic and cardiovascular complications. Best Pract Res Clin Obstet Gynaecol. 2015 Feb 1; 29(2):244–55. https://doi.org/10.1016/j.bpobgyn.2014.06.010 PMID: 25261964

9. Bottomley C, Bourne T. Diagnosing miscarriage. Vol. 23, Best Practice and Research: Clinical Obstetrics and Gynaecology. Best Pract Res Clin Obstet Gynaecol; 2009. p. 463–77. https://doi.org/10.1016/j.bpobgyn.2009.02.004 PMID: 19502113

10. Elish NJ, Saboda K, O’Connor J, Nasca PC, Stanek EJ, Boyle C. A prospective study of early pregnancy loss. Hum Reprod. 1996; 11(2):406–12. https://doi.org/10.1093/humrep/11.2.406 PMID: 8671233

11. Mosca L, Benjamin EJ, Berra K, Bezaslon JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update. Circulation. 2011 Mar 22; 123(11):1243–62. https://doi.org/10.1161/CIR.0b013e31820faaf8 PMID: 21325087

12. Oliver-Williams CT, Heydon EE, Smith GCS, Wood AM. Miscarriage and future cardiovascular disease: a systematic review and meta-analysis. Heart. 2013 Nov 15; 99(22):1636–44. https://doi.org/10.1136/heartjnl-2012-303237 PMID: 23539554

13. Wagner MM, Beshay MM, Rooijakkers S, Hermes W, Jukema JW, Le Cessie S, et al. Increased cardiovascular disease risk in women with a history of recurrent miscarriage. Acta Obstet Gynecol Scand. 2018 Oct 1; 97(10):1192–9. https://doi.org/10.1111/aogs.13392 PMID: 29806956

14. Wagner MM, Bhattacharya S, Visser J, Hannaford PC, Bloemenkamp KWM. Association between miscarriage and cardiovascular disease in a Scottish cohort. Heart. 2015 Dec 1; 101(24):1954–60. https://doi.org/10.1136/heartjnl-2015-307563 PMID: 26246401

15. Appelman Y, van Rijn BB, ten Haaf ME, Boersma E, Peters SAE. Sex differences in cardiovascular risk factors and disease prevention. Atherosclerosis. 2014 Nov 17; 241(1):211–8.

16. Germain AM, Romanik MC, Guerra I, Solarri S, Reyes MS, Johnson RJ, et al. Endothelial Dysfunction. Hypertension. 2007 Jan; 49(1):90–5. https://doi.org/10.1161/01.HYP.0000251522.18094.d4 PMID: 17116761

17. Smith G, Wood A, Pell J, Hattle J. Recurrent miscarriage is associated with a family history of ischaemic heart disease: a retrospective cohort study. BJOG An Int J Obstet Gynaecol. 2011 Apr; 118(5):557–63. https://doi.org/10.1111/j.1471-0528.2010.02890.x PMID: 21244619

18. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011; 19(4):251–5. https://doi.org/10.14236/jhi.v19i4.820 PMID: 22828580

19. Nick Booth (Centre for coding and classification, Woodgate, Loughborough LL 2TG. What are the Read codes. Health Libr Rev. 1994; II:177–88.

20. Martín-Merino E, Fortuny J, Rivero E, García-Rodríguez LA. Validation of diabetic retinopathy and maculopathy diagnoses recorded in a U.K. primary care database. Diabetes Care. 2012 Apr 1; 35 (4):762–7. https://doi.org/10.2337/dc12-2069 PMID: 22357184

21. Ruigómez A, Martín-Merino E, García Rodríguez LA. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoeconomics Drug Saf. 2010 Jun; 19(6):579–85. https://doi.org/10.1002/pds.1919 PMID: 20131328

22. Gokhale KM, Chandan JS, Touli K, Gkoutos G, Tino P, Niranharakumar K. Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies. Eur J Epidemiol. 2021 Feb 1; 36(2):165–78. https://doi.org/10.1007/s10654-020-00677-6 PMID: 32856160
23. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2009 Jan; 18 (1):76–83. https://doi.org/10.1002/pds.1688 PMID: 19065600

24. IVQIA.com. IQVIA Medical Research Data (IMRD) is non-identified electronic patient health record data collected from General Practitioner (GP) clinical systems via the IQVIA Medical Research Extraction Scheme and The Health Improvement Network (THIN) 2 Demonstrating.

25. Ooko K, Chandan JS, Marshall T, Thangaratnam S, Thomas GN, Niranharakumar K, et al. Association between the reproductive health of young women and cardiovascular disease in later life: Umbrella review. Vol. 371, The BMJ. BMJ Publishing Group; 2020. https://doi.org/10.1136/bmj.m3502 PMID: 33028606

26. Parikh NI, Norberg M, Ingelsson E, Cnattingius S, Vasan RS, Domelöf M, et al. Association of pregnancy complications and characteristics with future risk of elevated blood pressure. Hypertension. 2017 Mar 1; 69(3):475–83. https://doi.org/10.1161/HYPERTENSIONAHA.116.08121 PMID: 28137991

27. Kharazmi E, Fallah M, Luoto R. Miscarriage and risk of cardiovascular disease. Acta Obstet Gynecol Scand. 2010 Feb 1; 89(2):284–8. https://doi.org/10.3109/00016340903380758 PMID: 19943820

28. Ranthe MF, Andersen EAW, Wohlfahrh J, Bundgaard H, Melbye M, Boyd HA. Pregnancy Loss and Later Risk of Atherosclerotic Disease. Circulation. 2013 Apr 30; 127(17):1775–82. https://doi.org/10.1161/CIRCULATIONAHA.112.000285 PMID: 23536362

29. Horn J, Tanz LJ, Stuart JJ, Markovitz AR, Skurnik G, Rimm EB, et al. Early or late pregnancy loss and development of clinical cardiovascular disease risk factors: a prospective cohort study. BJOG An Int J Obstet Gynaecol. 2019 Jan 1; 126(1):33–42. https://doi.org/10.1111/1471-0528.15452 PMID: 30144277

30. Dawson SI, Smith WCS, Watson MS, Wilson BJ, Prescott GJ, Campbell D, et al. A cohort study of reproductive risk factors, weight and weight change and the development of diabetes mellitus. Diabetologia. 2003; 5(4):244–50. https://doi.org/10.1007/s00125-003-0269-x PMID: 12795657

31. Kharazmi E, Lukanova A, Teucher B, Große ML, Kaaka R. Does pregnancy or pregnancy loss increase later maternal risk of diabetes? Eur J Epidemiol. 2012 May 27; 27(5):357–66. https://doi.org/10.1007/s10654-012-9683-9 PMID: 22539240

32. Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Baillière's Best Pract Res Clin Obstet Gynaecol. 2000; 14(5):839–54. https://doi.org/10.1053/beog.2000.0123 PMID: 11023804

33. Bellamy L, Casas J-P, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009 May; 373(9677):1773–9. https://doi.org/10.1016/S0140-6736(09)60731-5 PMID: 19465232

34. Moran Ll, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. J Hum Reprod Update. 2010. p. 347–63. https://doi.org/10.1093/hummupd/dmq001 PMID: 20159883

35. Wu P, Kwok CS, Haithottoaru R, Kotronias RA, Babu A, Fryer AA, et al. Pre-eclampsia is associated with a twofold increase in diabetes: a systematic review and meta-analysis. Diabetologia. 2016 Dec 1; 59(12):2518–26. https://doi.org/10.1007/s00125-016-4098-x PMID: 27646865

36. Dubreuil M, Pho YH, Man A, Zhu Y, Zhang Y, Love TJ, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: A UK population-based cohort study. Rheumatol (Oxford). 2014 Feb; 53(2):346–52. https://doi.org/10.1093/rheumatology/keu543 PMID: 24185762

37. Peters SAE, Yang L, Guo Y, Chen Y, Bian Z, Sun H, et al. Pregnancy, pregnancy loss and the risk of diabetes in Chinese women: findings from the China Kadoorie Biobank. Eur J Epidemiol. 2020 Mar 1; 35(3):295–303. https://doi.org/10.1007/s10654-019-00582-7 PMID: 31745826

38. Li S, Zhang M, Tian H, Liu Z, Yin X, Xi B. Preterm birth and risk of type 1 and type 2 diabetes; systematic review and meta-analysis. Obes Rev. 2014 Oct 1; 15(10):804–11. https://doi.org/10.1111/obr.12214 PMID: 25073871

39. Sharma S, Yadav S, Chandio K, Sharma RS, Mishra V, Saraswathy KN. Protein signatures linking history of miscarriages and metabolic syndrome: a proteomic study among North Indian women. PeerJ. 2019; 7(2). https://doi.org/10.7717/peerj.6321 PMID: 30783564

40. Brakenhoff TB, Van Smeden M, Visseren FLJ, Groenewold RHI. Random measurement error: Why worry? An example of cardiovascular risk factors. PLoS One. 2018; 13(2):1–8. https://doi.org/10.1371/journal.pone.0192298 PMID: 29425217

41. Williams B, Mancia G, Spijer W, Rosel EA, Azizi M, Burnier M, et al. 2018 ESC Scientific Document Group, ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European...
42. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 1; 41(2):255–323.